Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR2 | P25025 | 18/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6699911 | 0.86 | CXCR2 (0.55) | CXCR2CYP2C9TDP1 | |
| SCHEMBL6695520 | 0.86 | CXCR2 (0.63) | CXCR2 | |
| SCHEMBL6978963 | 0.77 | CXCR2 (0.71) | CXCR2 | |
| SCHEMBL6973157 | 0.73 | CXCR2 (1.00) | CXCR2 | |
| SCHEMBL6982245 | 0.73 | CXCR2 (0.67) | CXCR2TDP1 | |
| SCHEMBL6975666 | 0.72 | CXCR2 (0.64) | CXCR2 | |
| SCHEMBL6979066 | 0.71 | CXCR2 (0.66) | CXCR2 | |
| SCHEMBL6699907 | 0.71 | CXCR2 (0.61) | CXCR2 | |
| SCHEMBL6978388 | 0.70 | CXCR2 (0.64) | CXCR2 | |
| SCHEMBL6976655 | 0.69 | CXCR2 (0.80) | CXCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040214864-A1 | Novel compounds | ASTRAZENECA AB (SE) | 2004-10-28 | — | — | US | claimed |
| EP-1274694-A1 | NOVEL COMPOUNDS | AstraZeneca AB (SE) | 2003-01-15 | — | — | EP | claimed |
| WO-2001077087-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2001-10-18 | — | — | WO | claimed |
| US-20040214864-A1 | Novel compounds | ASTRAZENECA AB (SE) | 2004-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040214864-A1 | Novel compounds | ABCG2, CYP3A4, CYP4B1 | CXCR2 568/4885CYP2C9 21/4885TDP1 2063/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.